Design Therapeutics, Inc. (DSGN)
15.11
-0.14
(-0.92%)
USD |
NASDAQ |
Aug 28, 16:00
15.09
-0.02
(-0.13%)
After-Hours: 20:00
Design Therapeutics 1 Year Total Returns (Daily) : 167.9% for Aug. 28, 2026
1 Year Total Returns (Daily) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical 1 Year Total Returns (Daily) Data
| Date | Value |
|---|---|
| August 28, 2026 | 167.9% |
| August 27, 2026 | 188.3% |
| August 26, 2026 | 188.2% |
| August 25, 2026 | 201.5% |
| August 24, 2026 | 189.5% |
| August 21, 2026 | 191.1% |
| August 20, 2026 | 224.8% |
| August 19, 2026 | 208.3% |
| August 18, 2026 | 182.8% |
| August 17, 2026 | 183.3% |
| August 14, 2026 | 187.4% |
| August 13, 2026 | 165.5% |
| August 12, 2026 | 194.4% |
| August 11, 2026 | 203.3% |
| August 10, 2026 | 234.8% |
| August 07, 2026 | 252.4% |
| August 06, 2026 | 216.6% |
| August 05, 2026 | 234.2% |
| August 04, 2026 | 233.3% |
| August 03, 2026 | 234.0% |
| July 31, 2026 | 214.7% |
| July 30, 2026 | 213.2% |
| July 29, 2026 | 202.0% |
| July 28, 2026 | 193.8% |
| July 27, 2026 | 195.5% |
| Date | Value |
|---|---|
| July 24, 2026 | 191.6% |
| July 23, 2026 | 172.4% |
| July 22, 2026 | 177.2% |
| July 21, 2026 | 197.8% |
| July 20, 2026 | 198.2% |
| July 17, 2026 | 212.7% |
| July 16, 2026 | 203.9% |
| July 15, 2026 | 244.5% |
| July 14, 2026 | 241.8% |
| July 13, 2026 | 253.4% |
| July 10, 2026 | 276.0% |
| July 09, 2026 | 269.8% |
| July 08, 2026 | 319.8% |
| July 07, 2026 | 315.5% |
| July 06, 2026 | 293.9% |
| July 02, 2026 | 325.0% |
| July 01, 2026 | 316.5% |
| June 30, 2026 | 329.4% |
| June 29, 2026 | 298.9% |
| June 26, 2026 | 249.5% |
| June 25, 2026 | 240.3% |
| June 24, 2026 | 247.1% |
| June 23, 2026 | 252.3% |
| June 22, 2026 | 266.3% |
| June 18, 2026 | 228.2% |
Total Return Definition
The Total return is the change in price over a specific period of time that includes dividends and distributions paid.
1 Year Total Returns (Daily) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
1 Year Total Returns (Daily) Benchmarks
| Amgen, Inc. | 55.58% |
| AnaptysBio, Inc. | 319.4% |
| 4D Molecular Therapeutics, Inc. | 137.4% |
| Inhibrx Biosciences, Inc. | 342.6% |
| Agenus, Inc. | 80.24% |